ImmuCell (ICCC) Set to Release Quarterly Earnings on Thursday

ImmuCell (NASDAQ:ICCC) is expected to announce its Q3 2026 results after the market closes on Thursday, November 12th. Analysts expect the company to post earnings of $0.05 per share and revenue of $5.40 million for the quarter. Parties may review the information on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Friday, November 13, 2026 at 9:00 AM ET.

ImmuCell (NASDAQ:ICCC) last released its quarterly earnings data on Thursday, August 13th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.05 by $0.15. The business had revenue of $7.19 million during the quarter, compared to analyst estimates of $5.40 million. ImmuCell had a return on equity of 2.69% and a net margin of 2.57%.

ImmuCell Price Performance

Shares of ICCC opened at $10.26 on Wednesday. ImmuCell has a 12 month low of $4.52 and a 12 month high of $12.10. The company has a debt-to-equity ratio of 0.22, a current ratio of 4.75 and a quick ratio of 2.71. The stock has a fifty day moving average price of $10.07 and a 200 day moving average price of $8.97. The company has a market cap of $93.16 million, a P/E ratio of 127.75 and a beta of 0.61.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings lowered shares of ImmuCell from a “hold (c)” rating to a “hold (c-)” rating in a research report on Wednesday, November 4th. One research analyst has rated the stock with a Hold rating. According to data from MarketBeat.com, ImmuCell presently has an average rating of “Hold”.

About ImmuCell

ImmuCell Corporation is a biotechnology and animal health company headquartered in Portland, Maine. The company develops, manufactures, and commercializes products designed to support the health and productivity of livestock, with a primary focus on cattle. ImmuCell’s products include FirstStep Calf Health, an on-farm diagnostic test that helps dairy and beef producers assess whether newborn calves have received adequate passive immunity from colostrum. The company also develops antibody-based products intended to help prevent or manage common diseases affecting young livestock, including neonatal calf diarrhea.